过继性免疫疗法用自然杀伤细胞的长期疗效：同种异体反应性 NK 细胞剂量仍然很重要。
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
机构信息
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Division of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy.
出版信息
Front Immunol. 2022 Jan 31;12:804988. doi: 10.3389/fimmu.2021.804988. eCollection 2021.
Recently, many reports were published supporting the clinical use of adoptively transferred natural killer (NK) cells as a therapeutic tool against cancer, including acute myeloid leukemia (AML). Our group demonstrated promising clinical response using adoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cells in AML patients. Moreover, the antileukemic effect was correlated with the dose of infused alloreactive NK cells ("functional NK cell dose"). Herein, we update the results of our previous study on a cohort of adult AML patients (median age at enrollment 64) in first morphological complete remission (CR), not eligible for allogeneic stem cell transplantation. After an extended median follow-up of 55.5 months, 8/16 evaluable patients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2 × 10/kg).
最近，有许多报告支持将过继转移的自然杀伤 (NK) 细胞作为一种治疗癌症的工具，包括急性髓细胞白血病 (AML)。我们的研究小组在 AML 患者中使用供体来源的同种异体反应性 KIR 配体不匹配 NK 细胞进行过继免疫治疗，显示出有前景的临床反应。此外，抗白血病效应与输注的同种异体反应性 NK 细胞的剂量（“功能性 NK 细胞剂量”）相关。在此，我们更新了我们之前在一组处于首次形态学完全缓解（CR）的成年 AML 患者（入组时的中位年龄为 64 岁）中的研究结果，这些患者不符合异基因干细胞移植的条件。在中位随访时间延长至 55.5 个月后，16 例可评估患者中有 8 例（50%）仍停药且无疾病存活。总生存（OS）和无病生存（DFS）与输注的同种异体反应性 NK 细胞的剂量（≥2×10/kg）相关。
Zotero 插件